in

Futures mixed as year end approaches; rate cuts in focus

Gains in megacap stocks in premarket trading kept the Nasdaq futures higher, while those tied to the S&P 500 remained subdued.

Wall Street managed to eke out some gains on Wednesday as all three indexes oscillated between modest gains and losses throughout the session, but finished higher for the day. All the indexes are on course for monthly, quarterly, and annual gains.

Focus will now be on the S&P 500. A closing above the January record close of 4796.56 would confirm the bellwether index entered a bull market after it hit the bear market closing trough in October 2022.

Traders will be closely monitoring the weekly jobless claims due at 8:30 a.m. ET as it is the last catalyst to influence the direction of markets before the end of 2023.

Optimism around early rate cuts with a possible soft landing for the American economy next year, and the artificial intelligence frenzy powered a rally in U.S. stocks in 2023, but fears of the economy slowing more sharply still persist as the full effect of higher borrowing costs filters through.

“Goldilocks is being counted on to make an appearance next year, with inflation cooling but the US economy staying warm enough, though there is still a risk that the bears return to prowl again,” said Susannah Streeter, head of money and markets, Hargreaves Lansdown.

Money markets have priced in an 86% probability that policymakers will reduce the Fed funds target rate by at least 25 basis points at the conclusion of their March policy meeting, according to CME’s FedWatch tool.

At 6:13 a.m. ET, Dow e-minis were down 49 points, or 0.13%, S&P 500 e-minis were up 0.75 points, or 0.02%, and Nasdaq 100 e-minis were up 37.75 points, or 0.22%.

Among individual stocks, U.S.-listed shares of Chinese companies rose in premarket trading as China’s blue-chip stocks staged their biggest jump in five months on Thursday on strong foreign inflows.

Shares of Alibaba (NYSE:BABA) Holdings, PDD Holdings and JD (NASDAQ:JD).Com Inc advanced between 1.4% and 3.7%.


Source: Economy - investing.com

Morgan Stanley’s straight-talking new CEO Ted Pick taking charge

Biden administration’s Medicare drug price negotiations will face major tests in 2024